BFBabalola Ooreofe Feranmi

Babalola Ooreofe Feranmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Babalola Ooreofe Feranmi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol

    by Israel Ogwuche Ogra, Aghogho Oyibo, Fabrice Banadzem Kernyuy, Ayomide Oluwaseun Adereti, Babalola Ooreofe Feranmi, Kayode Olayinka Afolabi, Glory Chinuru Musa, Vivian Onyinye Ojiakor, Umar-Farouq A. Mahe, Oluwatoyin Osinimega Ojo, et al.

    Background: Gestational diabetes mellitus (GDM) is a significant complication that can occur during pregnancy. It is characterized by glucose intolerance that first arises during pregnancy and is associated with insulin resistance, which is linked to elevated inflammatory markers. Metformin has emerged as a promising treatment option for GDM, with growing evidence supporting its anti-inflammatory effects. These effects are thought to be mediated by activation of AMP-activated protein kinase (AMPK) and inhibition of NF-κB signaling. This systematic review aims to assess the anti-inflammatory effects of metformin in GDM, considering both clinical and preclinical studies. Methods: A systematic review of all randomized controlled trials and controlled in vivo experiments for animals published until 2026 will be carried out. A comprehensive search of all published articles indexed in PubMed/MEDLINE, the Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase, and Web of Science will be performed. Studies will be screened for eligibility by title, abstract, and full text in duplicate by two independent reviewers. For data where meta-analysis is not possible, a narrative analysis will be conducted using themes derived from the data. For data that allow meta-analysis, a random-effects meta-analysis will be conducted. This systematic review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Discussion: The study will utilize meta-analysis to establish the anti-inflammatory effects of metformin in GDM, potentially influencing clinical practice and guidelines. Additionally, validating metformin’s anti-inflammatory effects has important implications beyond immediate management of GDM, extending to long-term adverse outcomes for both the mother and the offspring. Systematic review registration: PROSPERO CRD420261337881